EC Number   |
Activating Compound |
Reference |
|---|
   3.4.24.87 | plasmin |
truncation of the enzyme by plasmin enhances its activity in blood plasma |
755582 |
| 3.4.24.87 | Ristocetin |
activates |
650715 |
| 3.4.24.87 | Rituximab |
a monoclonal anti-CD 20 antibody, Rituximab leads to a prompt reduction in IgG antibody levels, followed by an increase in ADAMTS 13 activity increases. However, in patients receiving Rituximab electively, normalisation of ADAMTS 13 enzyme activity may be delayed for up to 3 months |
711559 |
| 3.4.24.87 | Urea |
activates at 1 M |
652481 |
| 3.4.24.87 | Urea |
activation, substrate is degraded at 1 M |
650717, 650725 |
| 3.4.24.87 | Urea |
required |
650714 |
| 3.4.24.87 | von Willebrand factor |
binding to substrate von Willebrand factor D4 allosterically activates ADAMTS13, increasing its catalytic activity. Binding also positions ADAMTS13 on the substrate where it can act rapidly when shear stress exposes the scissile bond in the adjacent A2 domain |
735184 |
| 3.4.24.87 | von Willebrand factor |
the enzyme is conformationally activated by von Willebrand factor which engages the TSP8-CUB2 domains, inducing the conformational change that disrupts the CUB1-spacer domain interaction and thereby activates the enzyme |
754157 |
